Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease

Canadian Journal of Neurological Sciences

Volumn 37, Issue 1, 2010, Pages 86-95

  Fox, Susan H ^a,b   Visanji, Naomi ^b   Reyes, Gaby ^b   Huot, Philippe ^b   Gomez Ramirez, Jordi ^b   Johnston, Tom ^b   Brotchie, Jonathan M ^b  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BENSERAZIDE PLUS LEVODOPA;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOREA; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFECT; DYSKINESIA; DYSTONIA; FEMALE; GROOMING; HYPERKINESIA; INTERRATER RELIABILITY; MARMOSET; MENTAL DISEASE; MOTOR DYSFUNCTION; NEUROPSYCHIATRY; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PHYSICAL DISABILITY; PRIORITY JOURNAL; RATING SCALE; SENSITIZATION; TREATMENT DURATION;

EID: 76649103713     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100009707     Document Type: Article

References (42)

1. Schrag A. Psychiatric aspects of Parkinson's disease--an update. J Neurol. 2004;251(7):795-804.
2. Weintraub D, Stern MB. Psychiatric complications in Parkinson disease. Am J Geriatr. Psychiatry. 2005;13(10):844-851
3. Ravina B, Marder K, Fernandez HH, Friedman JH, McDonald W, Murphy D, et al. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov Disord. 2007;22(8):1061-1068
4. Voon V, Fox SH. Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch Neurol. 2007;64(8): 1089-1096
5. Lawrence AD, Evans AH, Lees AJ. Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? Lancet Neurol. 2003;2(10):595-604.
6. Dodd ML, Klos KJ, Bower JH, Geda YE, Josephs KA, Ahlskog JE. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol. 2005;62(9):1377-1381
7. Nirenberg MJ, Waters C. Compulsive eating and weight gain related to dopamine agonist use. Mov Disord. 2006;21(4):524-529
8. Gallagher DA, O'Sullivan SS, Evans AH, Lees AJ, Schrag A. Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series. Mov Disord. 2007;22(12):1757-1763
9. Evans AH, Katzenschlager R, Paviour D, O'Sullivan JD, Appel S, Lawrence AD, et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord. 2004;19 (4):397-405.
10. Kurlan R. Disabling repetitive behaviors in Parkinson's disease. Mov Disord. 2004;19(4):433-437
11. Galpern WR, Stacy M. Management of impulse control disorders in Parkinson's disease. Curr Treat Options Neurol. 2007;9(3): 189-197
12. Kimber TE, Thompson PD, Kiley MA. Resolution of dopamine dysregulation syndrome following cessation of dopamine agonist therapy in Parkinson's disease. J Clin Neurosci. 2008;15 (2):205-208
13. Factor SA, Feustel PJ, Friedman JH, Comella CL, Goetz CG, Kurlan R, et al. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology. 2003;60(11):1756-1761
14. Rajput AH, Fenton ME, Birdi S, Macaulay R, George D, Rozdilsky B, et al. Clinical-pathological study of levodopa complications. Mov Disord. 2002;17(2):289-296
15. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med. 2000;342(20): 1484-1491
16. Visanji NP, Gomez-Ramirez J, Johnston TH, Pires D, Voon V, Brotchie JM, et al. Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord. 2006;21(11): 1879-1891
17. Fox SH, Visanji NP, Johnston TH, Gomez-Ramirez J, Voon V, Brotchie JM. Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease. Arch Neurol. 2006;63(9):1343-1344
18. Scraggs PR, Ridley RM. Behavioural effects of amphetamine in a small primate: relative potencies of the d- and l-isomers. Psychopharmacology (Berl). 1978;59(3):243-245
19. Castner SA, Goldman-Rakic PS. Long-lasting psychotomimetic consequences of repeated low-dose amphetamine exposure in rhesus monkeys. Neuropsychopharmacology. 1999;20(1):10-28.
20. Pearce RK, Jackson M, Smith L, Jenner P, Marsden CD. Chronic LDOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6- tetrahydropyridine-treated common marmoset (Callithrix Jacchus). Mov Disord. 1995;10(6):731-740
21. Fox SH, Henry B, Hill M, Crossman A, Brotchie J. Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord. 2002;17(6):1180-1187
22. Jenner P, Rupniak NM, Rose S, Kelly E, Kilpatrick G, Lees A, et al. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset. Neurosci Lett. 1984;50 (1-3):85-90.
23. Henry B, Fox SH, Crossman AR, Brotchie JM. Mu- and deltaopioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Exp Neurol. 2001;171(1):139-146
24. Segal DS, Weinberger SB, Cahill J, McCunney SJ. Multiple daily amphetamine administration: behavioral and neurochemical alterations. Science. 1980;207(4433):905-907
25. Robinson TE, Berridge KC. Incentive-sensitization and addiction. Addiction. 2001;96(1):103-114
26. Schmidt WJ, Beninger RJ. Behavioural sensitization in addiction, schizophrenia, Parkinson's disease and dyskinesia. Neurotox Res. 2006;10(2):161-166
27. Kimura M. Role of basal ganglia in behavioral learning. Neurosci Res. 1995;22(4):353-358
28. Knowlton BJ, Mangels JA, Squire LR. A neostriatal habit learning system in humans. Science. 1996;273(5280):1399-1402
29. Schultz W. Dopamine neurons and their role in reward mechanisms. Curr Opin Neurobiol. 1997;7(2):191-197
30. Costall B, Naylor RJ, Cannon JG, Lee T. Differentiation of the dopamine mechanisms mediating stereotyped behaviour and hyperactivity in the nucleus accumbens and caudate-putamen. J Pharm Pharmacol. 1977;29(6):337-342
31. Graybiel AM, Canales JJ, Capper-Loup C. Levodopa-induced dyskinesias and dopamine-dependent stereotypies: a new hypothesis. Trends Neurosci. 2000;2323 Suppl 10:S71-7.
32. Evans AH, Pavese N, Lawrence AD, Tai YF, Appel S, Doder M, et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol. 2006;59(5):852-858
33. Pierce RC, Kalivas PW. A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Brain Res Rev. 1997;25(2):192-216.
34. Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopainduced dyskinesia: potential for new therapies. Nat Rev Neurosci. 2001;2(8):577-588
35. Zhang X, Lee TH, Davidson C, Lazarus C, Wetsel WC, Ellinwood EH. Reversal of cocaine-induced behavioral sensitization and associated phosphorylation of the NR2B and GluR1 subunits of the NMDA and AMPA receptors. Neuropsychopharmacology. 2007;32(2):377-387
36. Smiley PL, Johnson M, Bush L, Gibb JW, Hanson GR. Effects of cocaine on extrapyramidal and limbic dynorphin systems. J Pharmacol Exp Ther. 1990;253(3):938-943
37. Duty S, Henry B, Crossman AR, Brotchie JM. Topographical organization of opioid peptide precursor gene expression following repeated apomorphine treatment in the 6- hydroxydopamine-lesioned rat. Exp Neurol. 1998;150(2): 223-234
38. Henry B, Duty S, Fox SH, Crossman AR, Brotchie JM. Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease. Exp Neurol. 2003;183(2): 458-468
39. Crossman AR. A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. Mov Disord. 1990;5(2):100-108
40. Alexander GE, Crutcher MD, DeLong MR. Basal gangliathalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. Prog Brain Res. 1990;85:119-146
41. Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev. 1993;18(3):247-291
42. Canales JJ, Graybiel AM. Patterns of gene expression and behavior induced by chronic dopamine treatments. Ann Neurol. 2000;47(4 Suppl 1):S53-9.